Records 1-15 (of 15 Records) |
Query Trace: Developmental Disabilities[original query] |
---|
Clusters of SARS-CoV-2 Infection Across Six Schools for Students with Intellectual and Developmental Disabilities. Gemmell Michael, et al. Infectious diseases and therapy 2023 0 0. |
Management and support of individuals with developmental disabilities during the COVID-19 pandemic. Dimitriou Dagmara, et al. Research in developmental disabilities 2022 0 0. 104228 |
The COVID-19 pandemic's impact on worry and medical disruptions reported by individuals with chromosome 22q11.2 copy number variants and their caregivers. White L K, et al. Journal of intellectual disability research : JIDR 2022 0 0. |
Linked nosocomial COVID-19 outbreak in three facilities for people with intellectual and developmental disabilities due to SARS-CoV-2 variant B.1.1.519 with spike mutation T478K in the Netherlands. Gorgels Koen M F, et al. BMC infectious diseases 2022 0 0. (1) 139 |
Severe Outcomes, Readmission, and Length of Stay Among COVID-19 Patients with Intellectual and Developmental Disabilities. Koyama Alain K, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2022 0 0. |
Covid Vaccines for Children with Developmental Disabilities: Parent Survey of Willingness and Concerns K Bonuck et al, MEDRXIV, December 23, 2021 |
SARS-CoV-2 screening testing in schools for children with intellectual and developmental disabilities. Sherby Michael R, et al. Journal of neurodevelopmental disorders 2021 0 0. (1) 31 |
Talking to Patients with Intellectual and Developmental Disabilities about COVID-19 Vaccination- Tips for Healthcare Providers & Clinical Staff CDC, August 2021
There are an estimated 7.38 million people with intellectual and developmental disabilities in the United States. When you’re talking with patients who have intellectual and developmental disabilities, it’s especially important to make sure your message about COVID-19 vaccination is simple and clear. People with ID/DDs may: Have limited mobility; Difficulty accessing information; Require close contact with a care provider; Have trouble understanding information; Have difficulties with changes in routines; Have other concerns related to their disability.
|
COVID-19 positivity rates, hospitalizations and mortality of adults with and without intellectual and developmental disabilities in Ontario, Canada. Lunsky Y, et al. Disability and health journal 2021 0 0. 101174 |
Risk Factors Associated With COVID-19 Outcomes Among People With Intellectual and Developmental Disabilities Receiving Residential Services. Landes Scott D, et al. JAMA network open 2021 0 0. (6) e2112862 |
Applying Genomic Epidemiology to Characterize a COVID-19 Outbreak in a Developmentally Disabled Adult Group Home Setting, Arizona. Yaglom Hayley D et al. Frontiers in public health 2021 6 668214 |
Impact of COVID-19 outbreak on mental health and perceived strain among caregivers tending children with special needs. Dhiman Sapna, et al. Research in developmental disabilities 2020 12 0. 103790 |
Changes in access to educational and healthcare services for individuals with intellectual and developmental disabilities during COVID-19 restrictions. Jeste S, et al. Journal of intellectual disability research : JIDR 2020 9 0. |
Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis. Turk Margaret A et al. Disability and health journal 2020 May 100942
Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis. Turk Margaret A, Landes Scott D, Formica Margaret K, Goss Katherine D Turk Margaret A et al. Disability and health journal 2020 May 100942 Disability and health journal Despite possibly higher risk of severe outcomes from COVID-19 among people with intellectual and developmental disabilities (IDD), there has been limited reporting of COVID-19 trends for this population.To compare COVID-19 trends among people with and without IDD, overall and stratified by age.Data from the TriNetX COVID-19 Research Network platform was used to identify COVID-19 patients. Analysis focused on trends in comorbidities, number of cases, number of deaths, and case-fatality rate among patients with and without IDD who had a positive diagnosis for COVID-19 through May 14, 2020.People with IDD had higher prevalence of specific comorbidities associated with poorer COVID-19 outcomes. Distinct age-related differences in COVID-19 trends were present among those with IDD, with a higher concentration of COVID-19 cases at younger ages. In addition, while the overall case-fatality rate was similar for those with IDD (5.1%) and without IDD (5.4%), these rates differed by age: ages =17 - IDD 1.6%, without IDD <0.01%; ages 18-74 - IDD 4.5%, without IDD 2.7%; ages =75- IDD 21.1%, without IDD, 20.7%.Though of concern for all individuals, COVID-19 appears to present a greater risk to people with IDD, especially at younger ages. Future research should seek to document COVID-19 trends among people with IDD, with particular attention to age related trends.Copyright © 2020 Elsevier Inc. All rights reserved. Developmental Disabilities Developmental Disabilities People with intellectual and developmental disabilities had higher prevalence of specific comorbidities associated with poorer COVID-19 outcomes. Distinct age-related differences in COVID-19 trends were present among those with IDD, with a higher concentration of COVID-19 cases at younger ages.
|
Coronaviruses and people with intellectual disability: an exploratory data analysis. Tummers J, et al. Journal of intellectual disability research : JIDR 2020 4 0. |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 25, 2024
- Content source: